Target intelligence / Profile preview

Ribosomal protein L26 pseudogene 3 (RPL26P3)

Target
RPL26P3
Molecular classification
Other (Pseudogene), Ribosomal protein pseudogene
01

Overview

Ribosomal protein L26 pseudogene 3 (RPL26P3) is a processed pseudogene found in the human genome. Pseudogenes are DNA sequences similar to functional genes but generally lack protein-coding ability due to accumulated mutations. RPL26P3 is derived from the gene encoding ribosomal protein L26, a structural component of the large 60S ribosomal subunit and part of the universal ribosomal protein family. While ribosomal protein L26 (RPL26) plays an essential role in protein synthesis, its pseudogenes (such as RPL26P3) are non-functional, do not encode proteins, and have no known biological activities or therapeutic relevance[1][2][4]. Summary of classification and relevance: RPL26P3 is a non-coding, non-functional pseudogene related to ribosomal protein L26, with no known biological function, disease association, or role as a drug target. It should not be considered a therapeutic target. There is nothing incorrect about its naming or description, but its inclusion in pharmacological or therapeutic target lists would be inappropriate as it does not meet functional criteria for such classification[1][2].

Other names
RPL26P3RPL26_17_1344Ribosomal protein L26 pseudogene 3
02

Mechanism of action

None (as there are no drugs targeting this pseudogene[1][2])

03

Biological functions

None (as a pseudogene, RPL26P3 does not have known biological functions; it is a non-functional genomic locus derived from ribosomal protein L26[1][2])Some pseudogenes may occasionally regulate gene expression at the RNA level, but there is no specific evidence for such a function for RPL26P3[1][2].
04

Disease associations

None (no direct role in human disease; functional RPL26 protein, not RPL26P3, is associated with certain conditions such as Diamond-Blackfan anemia, but the pseudogene itself is not[4][13])Other (pseudogenes generally do not have direct disease associations unless specifically implicated in gene regulation or chromosomal abnormalities, which is not the case here)
05

Safety considerations

None (no safety concerns associated with RPL26P3, as it is not targeted therapeutically or considered in clinical safety evaluations[1][2])
06

Interacting drugs

None (no known drugs interact with RPL26P3[1][2])
07

Biomarkers

None (RPL26P3 is not used as a biomarker for patient selection or efficacy monitoring[1][2])

Beyond the preview

Go deeper on Ribosomal protein L26 pseudogene 3 (RPL26P3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L26 pseudogene 3 (RPL26P3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call